<DOC>
	<DOCNO>NCT00132015</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , 17-N-allylamino-17-demethoxygeldanamycin ( 17-AAG ) , work different way stop growth tumor cell , either kill cell stop dividing . PURPOSE : This phase II trial study well 17-AAG work treat patient systemic mastocytosis .</brief_summary>
	<brief_title>17-N-Allylamino-17-Demethoxygeldanamycin Treating Patients With Systemic Mastocytosis</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine efficacy 17-N-allylamino-17-demethoxygeldanamycin ( 17-AAG ) , term decrease number mast cell bone marrow serum tryptase level , patient systemic mastocytosis . Secondary - Determine quality life patient treated drug . - Determine hematological non-hematological toxicity drug patient . OUTLINE : This multicenter study . Patients receive 17-N-allylamino-17-demethoxygeldanamycin ( 17-AAG ) IV 2-6 hour day 1 , 4 , 8 , 11 . Treatment repeat every 21 day least 6 course absence disease progression unacceptable toxicity . Patients achieve complete response ( CR ) receive least 2 additional course beyond CR . Patients achieve partial response receive least 4 additional course beyond maximum response . Selected patient may receive additional course therapy beyond protocol guideline discretion principal investigator . Quality life assess baseline treatment course . PROJECTED ACCRUAL : A total 12-37 patient accrue study within approximately 10-18 month .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Mastocytosis</mesh_term>
	<mesh_term>Precancerous Conditions</mesh_term>
	<mesh_term>Mastocytosis , Systemic</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm systemic mastocytosis Objective evidence disease , define follow : Hemoglobin &lt; 10 g/dL Recurrent mast cell mediatorrelease symptom impair patient 's quality life Symptomatic hepatosplenomegaly Ascites Symptomatic bone disease Profound constitutional symptom ( e.g. , fatigue , asthenia , flushing , hyperpyrexia , weight loss , myalgia , arthralgia ) Elevated serum tryptase level Mast cell leukemia allow Mastocytosis associate myeloproliferative disease ( e.g. , hypereosinophilic syndrome chronic myelomonocytic leukemia ) allow Patients eosinophilia ( i.e. , absolute eosinophil count ≥ 1,000/mm^3 ) must evaluate presence absence FIP1L1PDGFRA mutation ; mutation absent , patient eligible ; mutation present , patient eligible provide disease refractory imatinib mesylate Patients indolent disease must serum tryptase level ≥ 50 ng/mL OR episodes anaphylaxis occur frequency &gt; 1 per month PATIENT CHARACTERISTICS : Age 18 Performance status ECOG 02 Life expectancy At least 3 month Hematopoietic See Disease Characteristics Platelet count ≥ 100,000/mm^3 ( &gt; 25,000/mm^3 patient organomegaly ) Absolute granulocyte count ≥ 1,500/mm^3 ( &gt; 750/mm^3 patient organomegaly ) Hepatic AST ALT ≤ 2 time upper limit normal ( ULN ) ( &lt; 4 time ULN patient hepatomegaly ) Bilirubin normal Alkaline phosphatase ≤ 3 time ULN Renal Creatinine ≤ 1.4 mg/dL OR Creatinine clearance ≥ 60 mL/min Cardiovascular No New York Heart Association class IIIIV congestive heart failure No history myocardial infarction within past year No history uncontrolled dysrhythmia No uncontrolled angina No ischemic heart disease within past 12 month No congenital long QT syndrome No leave bundle branch block No serious ventricular arrhythmia ( ventricular tachycardia ventricular fibrillation ≥ 3 beat row ) QTc interval &lt; 450 msec male 470 msec female LVEF &gt; 40 % MUGA MUGA echocardiogram normal No prior history cardiac toxicity receive anthracyclines ( e.g. , doxorubicin hydrochloride , daunorubicin hydrochloride , mitoxantrone hydrochloride , bleomycin , carmustine ) No cardiac symptom ≥ grade 2 No significant cardiac disease Pulmonary No symptomatic pulmonary disease require medication include follow : Dyspnea exertion Paroxysmal nocturnal dyspnea Requirement oxygen Significant pulmonary disease ( e.g. , chronic obstructive/restrictive pulmonary disease ) No home oxygen meeting Medicare requirement No compromise pulmonary status ( i.e. , DLCO ≤ 80 % ) No prior history pulmonary toxicity receive anthracyclines ( e.g. , doxorubicin hydrochloride , daunorubicin hydrochloride , mitoxantrone hydrochloride , bleomycin , carmustine ) No pulmonary symptom ≥ grade 2 Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception ≥ 6 month completion study treatment HIV negative No active uncontrolled infection No serious medical illness No nonmalignant systemic disease No history serious allergic reaction egg No malignancy within past 2 year except dermatological cancer PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy At least 4 week since prior chemotherapy Endocrine therapy Steroids allow provide taper low level possible treat thrombocytopenia , diarrhea , malabsorption symptom systemic mastocytosis Radiotherapy At least 4 week since prior radiotherapy No prior radiation include heart field ( e.g. , mantle ) chest Surgery Not specify Other At least 4 week since prior tyrosine kinase inhibitors No concurrent complimentary alternative medications* include , limited , follow : Hypericum perforatum ( St. John 's wort ) Milk thistle Kava kava Mistletoe extract No concurrent agent cause QTc prolongation No concurrent antiarrhythmic therapy No concurrent investigational therapy NOTE : *Unless approve investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Waldenström macroglobulinemia</keyword>
	<keyword>multicentric Castleman disease</keyword>
	<keyword>unicentric Castleman disease</keyword>
	<keyword>adult grade III lymphomatoid granulomatosis</keyword>
	<keyword>polycythemia vera</keyword>
	<keyword>essential thrombocythemia</keyword>
	<keyword>hairy cell leukemia</keyword>
	<keyword>monoclonal gammopathy undetermined significance</keyword>
	<keyword>adult Burkitt lymphoma</keyword>
	<keyword>adult diffuse large cell lymphoma</keyword>
	<keyword>adult diffuse mixed cell lymphoma</keyword>
	<keyword>adult diffuse small cleave cell lymphoma</keyword>
	<keyword>adult immunoblastic large cell lymphoma</keyword>
	<keyword>adult lymphoblastic lymphoma</keyword>
	<keyword>grade 1 follicular lymphoma</keyword>
	<keyword>grade 2 follicular lymphoma</keyword>
	<keyword>grade 3 follicular lymphoma</keyword>
	<keyword>mantle cell lymphoma</keyword>
	<keyword>marginal zone lymphoma</keyword>
	<keyword>small lymphocytic lymphoma</keyword>
	<keyword>precancerous condition</keyword>
</DOC>